Blenrep, which is predicted by analysts to produce revenues of around $1.5bn in 2026, is an antibody-drug conjugate that works by targeting B-cell maturation antigen (BCMA), a protein commonly ...

While Blenrep has been granted accelerated approval by the FDA for multiple myeloma patients who have received at least four prior therapies – including an anti-CD38 monoclonal antibody, a ...

The BTD was granted based on the interim results of the Phase III DREAMM-7 trial, which met its primary endpoint.

No writing assistance was utilized in the production of this manuscript. Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA).

The sequence homology is over 95%; PTM and aggregation prediction reports are also available 100% success rate As quick as 3–4 weeks to offer required humanized antibodies Affinity evaluated by ...

Examples of antibody sequences accepted: variable region sequenced from hybridoma, hits (Fab or scFv) selected from display library based method, sequences from single B cell and/or repertoire ...

The London-based pharmaceutical company said Japan's Ministry of Health, Labour and Welfare has accepted the application to review its Blenrep antibody drug in combination with BorDex or PomDex as ...

Antigens include allergens, bacteria and viruses. Antibodies are Y-shaped proteins that the body produces when it detects antigens. Antibodies are produced by immune cells called B cells. Antigens are ...

The London-based pharmaceutical company said Japan's Ministry of Health, Labour and Welfare has accepted the application to review its Blenrep antibody drug in combination with BorDex or PomDex as a ...